Canagliflozin and Renal Outcomes in Type 2 Diabetes and NephropathyVlado Perkovic, Kenneth W. Mahaffey, Hiddo J.L. Heerspink et al.|New England Journal of Medicine|2019Cited by 6k
Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trialKarin Hardt, Jeffrey J. Stoddard, An Vandebosch et al.|The Lancet Infectious Diseases|2022Cited by 88